Royce & Associates LP Invests $811,000 in Omnicell, Inc. (NASDAQ:OMCL)

Royce & Associates LP acquired a new position in Omnicell, Inc. (NASDAQ:OMCL) during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor acquired 18,597 shares of the company’s stock, valued at approximately $811,000.

Several other hedge funds and other institutional investors also recently bought and sold shares of OMCL. Arizona State Retirement System lifted its holdings in shares of Omnicell by 2.9% in the 2nd quarter. Arizona State Retirement System now owns 12,853 shares of the company’s stock worth $348,000 after buying an additional 357 shares during the period. Diversified Trust Co raised its holdings in shares of Omnicell by 3.3% in the second quarter. Diversified Trust Co now owns 15,364 shares of the company’s stock valued at $416,000 after acquiring an additional 494 shares in the last quarter. GAMMA Investing LLC lifted its stake in Omnicell by 78.4% in the third quarter. GAMMA Investing LLC now owns 1,258 shares of the company’s stock worth $55,000 after acquiring an additional 553 shares during the period. Louisiana State Employees Retirement System grew its holdings in Omnicell by 2.7% during the 2nd quarter. Louisiana State Employees Retirement System now owns 23,100 shares of the company’s stock worth $625,000 after acquiring an additional 600 shares in the last quarter. Finally, ProShare Advisors LLC increased its position in Omnicell by 7.4% during the 1st quarter. ProShare Advisors LLC now owns 9,076 shares of the company’s stock valued at $265,000 after purchasing an additional 626 shares during the period. Institutional investors own 97.70% of the company’s stock.

Omnicell Price Performance

Shares of NASDAQ:OMCL opened at $41.82 on Thursday. The business’s 50-day moving average is $44.21 and its 200 day moving average is $37.17. Omnicell, Inc. has a 1 year low of $25.12 and a 1 year high of $55.74. The firm has a market capitalization of $1.94 billion, a P/E ratio of -107.23, a P/E/G ratio of 43.97 and a beta of 0.81.

Analysts Set New Price Targets

A number of equities analysts have recently issued reports on the stock. Bank of America reiterated a “neutral” rating and set a $57.00 price objective (up from $44.00) on shares of Omnicell in a research note on Thursday, October 31st. Barclays increased their target price on Omnicell from $39.00 to $58.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Craig Hallum boosted their price target on Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research report on Thursday, October 31st. StockNews.com downgraded Omnicell from a “buy” rating to a “hold” rating in a research report on Friday, November 15th. Finally, Wells Fargo & Company boosted their target price on shares of Omnicell from $30.00 to $41.00 and gave the stock an “equal weight” rating in a report on Monday, October 14th. Five research analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $50.83.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.